Cambrex Corporation  

(Public, NYSE:CBM)   Watch this stock  
Find more results for CBM
53.75
+0.25 (0.47%)
Real-time:   3:06PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 53.20 - 54.15
52 week 38.30 - 62.95
Open 53.55
Vol / Avg. 56,733.00/303,680.00
Mkt cap 1.75B
P/E 19.01
Div/yield     -
EPS 2.83
Shares 32.57M
Beta 2.09
Inst. own 108%
Jul 26, 2017
Q2 2017 Cambrex Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 31, 2017
Cambrex Corp at Craig-Hallum Institutional Investor Conference Add to calendar
May 22, 2017
Cambrex Corp at UBS Global Healthcare Conference - Webcast
May 4, 2017
Q1 2017 Cambrex Corp Earnings Release
May 4, 2017
Q1 2017 Cambrex Corp Earnings Call - Webcast
Apr 27, 2017
Cambrex Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 20.11% 17.80%
Operating margin 25.89% 26.16%
EBITD margin - 31.42%
Return on average assets 13.67% 15.63%
Return on average equity 20.26% 24.38%
Employees 1,295 -
CDP Score - -

Address

1 Meadowlands Plz
E RUTHERFORD, NJ 07073-2150
United States - Map
+1-201-8043000 (Phone)
+1-201-8049852 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Officers and directors

Steven Mark Klosk President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Tom George Vadaketh Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Shawn P. Cavanagh Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory P. Sargen Executive Vice President, Corporate Development and Strategy
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Samantha M. Hanley Vice President, General Counsel,Corporate Secretary
Age: 39
Bio & Compensation  - Reuters
James G. Farrell Vice President and Corporate Controller
Age: 50
Bio & Compensation  - Reuters
Shlomo Yanai Non-Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Rosina B. Dixon M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Claes Glassell Independent Director
Age: 65
Bio & Compensation  - Reuters
Louis J. Grabowsky Independent Director
Age: 65
Bio & Compensation  - Reuters